RS78004A - Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist - Google Patents

Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Info

Publication number
RS78004A
RS78004A YU78004A YUP78004A RS78004A RS 78004 A RS78004 A RS 78004A YU 78004 A YU78004 A YU 78004A YU P78004 A YUP78004 A YU P78004A RS 78004 A RS78004 A RS 78004A
Authority
RS
Serbia
Prior art keywords
pde3
pde4
inhibitor
pharmaceutical composition
histamine receptor
Prior art date
Application number
YU78004A
Other languages
English (en)
Inventor
Christian Weimar
Daniela Bundschuh
Rolf Beume
Stefan-Lutz Wollin
Original Assignee
Altana Pharma Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag. filed Critical Altana Pharma Ag.
Publication of RS78004A publication Critical patent/RS78004A/sr
Publication of RS51018B publication Critical patent/RS51018B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ovaj pronalazak se odnosi na kombinovanu primenu inhibitora PDE4 ili inhibitora PDE3/4 i antaghonista histaminskih receptora u lečenju respiratornih oboljenja.
YUP-780/04A 2002-03-06 2003-02-25 Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora RS51018B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06
PCT/EP2003/001876 WO2003074055A1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (2)

Publication Number Publication Date
RS78004A true RS78004A (en) 2006-12-15
RS51018B RS51018B (sr) 2010-10-31

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-780/04A RS51018B (sr) 2002-03-06 2003-02-25 Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora

Country Status (32)

Country Link
US (1) US20050112069A1 (sr)
EP (2) EP1849468B1 (sr)
JP (1) JP5150034B2 (sr)
KR (1) KR20040095255A (sr)
CN (1) CN101257904A (sr)
AR (1) AR038858A1 (sr)
AT (1) ATE369134T1 (sr)
AU (1) AU2003212268B2 (sr)
BR (1) BR0308220A (sr)
CA (1) CA2478612C (sr)
CO (1) CO5611148A2 (sr)
CY (2) CY1106927T1 (sr)
DE (1) DE60315426T2 (sr)
DK (2) DK1482938T3 (sr)
EA (2) EA007903B1 (sr)
ES (2) ES2291618T3 (sr)
HK (1) HK1071308A1 (sr)
HR (1) HRP20040909B1 (sr)
IL (1) IL163336A (sr)
IS (2) IS2536B (sr)
MX (1) MXPA04008460A (sr)
NO (1) NO335254B1 (sr)
NZ (1) NZ535611A (sr)
PL (1) PL211574B1 (sr)
PT (2) PT1849468E (sr)
RS (1) RS51018B (sr)
SG (1) SG160197A1 (sr)
SI (2) SI1849468T1 (sr)
TW (1) TWI347845B (sr)
UA (1) UA80117C2 (sr)
WO (1) WO2003074055A1 (sr)
ZA (1) ZA200407104B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080065704A (ko) * 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
ES2341813T3 (es) * 2006-12-20 2010-06-28 Glaxo Group Limited 4-bencil-1 (2h)-ftalazinonas como antagonistas del receptor h1.
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
PL2672957T3 (pl) 2011-02-07 2017-05-31 Scipharm Sàrl Nowe kompozycje do leczenia mukowiscydozy
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
JP2017525721A (ja) * 2014-08-26 2017-09-07 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
EP3205652B1 (en) 2014-10-09 2022-03-09 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and applications thereof
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
KR100331255B1 (ko) * 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
PL354979A1 (en) * 1999-10-25 2004-03-22 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
JP2005524666A (ja) 2005-08-18
CY1106927T1 (el) 2012-09-26
IS7438A (is) 2004-09-03
TW200306855A (en) 2003-12-01
PL211574B1 (pl) 2012-05-31
DE60315426D1 (de) 2007-09-20
ES2400670T3 (es) 2013-04-11
EA007903B1 (ru) 2007-02-27
EP1482938B1 (en) 2007-08-08
HRP20040909B1 (en) 2012-11-30
CA2478612A1 (en) 2003-09-12
EP1482938A1 (en) 2004-12-08
CA2478612C (en) 2013-12-10
JP5150034B2 (ja) 2013-02-20
AU2003212268B2 (en) 2008-09-11
CO5611148A2 (es) 2006-02-28
NZ535611A (en) 2006-03-31
SI1482938T1 (sl) 2007-12-31
BR0308220A (pt) 2005-01-04
PT1849468E (pt) 2013-02-27
DK1482938T3 (da) 2007-12-03
CN101257904A (zh) 2008-09-03
SI1849468T1 (sl) 2013-03-29
ES2291618T3 (es) 2008-03-01
DK1849468T3 (da) 2013-02-04
ZA200407104B (en) 2006-12-27
SG160197A1 (en) 2010-04-29
AR038858A1 (es) 2005-01-26
NO335254B1 (no) 2014-10-27
NO20044230L (no) 2004-12-06
IS8760A (is) 2008-09-04
CY1113894T1 (el) 2016-07-27
EA200601592A1 (ru) 2006-12-29
US20050112069A1 (en) 2005-05-26
EP1849468A2 (en) 2007-10-31
EP1849468A3 (en) 2007-11-07
EA010886B1 (ru) 2008-12-30
PT1482938E (pt) 2007-11-15
HRP20040909A2 (en) 2005-08-31
HK1071308A1 (en) 2005-07-15
UA80117C2 (uk) 2007-08-27
AU2003212268A1 (en) 2003-09-16
IS2536B (is) 2009-08-15
MXPA04008460A (es) 2004-12-06
DE60315426T2 (de) 2008-07-03
PL371056A1 (en) 2005-06-13
WO2003074055A1 (en) 2003-09-12
EP1849468B1 (en) 2012-12-05
TWI347845B (en) 2011-09-01
IL163336A (en) 2009-02-11
RS51018B (sr) 2010-10-31
ATE369134T1 (de) 2007-08-15
KR20040095255A (ko) 2004-11-12
EA200401137A1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
GEP20084571B (en) Triazole derivatives as vasopressin antagonists
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
ATE450508T1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
TW200621261A (en) Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
ID29818A (id) Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial
AU2003226765A8 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
BR0000486A (pt) Antagonistas do neuropeptìdeo y
WO2003105891A3 (en) USE OF HEC1 ANTAGONISTS IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND CANCERS
NO20033634L (no) GLyT-1-inhibitorer